Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David M. Bedwell
University of Alabama at Birmingham, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genzyme Corporation
Other : IP from awardee institution
The investigator’s IP is used in project or is closely related to that which is used and thus its value could be impacted by the results.
New Nonsense Suppression Drugs to Treat MPS I
This application will test whether two new drugs that suppress translation termination at nonsense mutations can restore enough functional protein to reduce the disease progression of mucopolysaccharidosis I-Hurler (MPS I-H), a disease frequently caused by nonsense mutations. These drugs penetrate brain tissue and may relieve MPS I-H neurological defects. In addition, these drugs may also alleviate other MPS I-H defects that are resistant to current MPS I-H treatments.
Filed on October 09, 2014.
Tell us what you know about David M. Bedwell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
David M. Bedwell filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David M. Bedwell | University of Alabama at Birmingham | Conflict of Interest | PTC THERAPEUTICS, INC. | $40,000 - $59,999 |
| David M. Bedwell | University of Alabama at Birmingham | Conflict of Interest | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | $0 - $4,999 |
| David M. Bedwell | University of Alabama at Birmingham | Conflict of Interest | BIOMARIN PHARMACEUTICAL, INC. | $0 - $4,999 |
| David M. Bedwell | University of Alabama at Birmingham | Conflict of Interest | VECTALYS | $0 - $4,999 |
| David M. Bedwell | University of Alabama at Birmingham | Conflict of Interest | PTC THERAPEUTICS, INC. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.